People wanting to keep wrinkles at bay will soon have a new option now that the FDA has approved the first competitor for Botox in decades.
The company has begun testing the drug on these other medical issues, Foley said. While the company had been trying to create a product that needed no needle, it instead discovered a way to use peptide technology to keep the product stable. Typically, animal protein or human serum is used.
Botox is also used for more than just wrinkles. It has been an FDA-approved treatment for chronic migraines since 2010. Users of Daxxify in the Revance studies included some who experienced side effects. About 2% of people developed a drooping eyelid, while about 6% experienced headache, the company said.
Toxin-based treatment can carry the potential for other side effects, such as general muscle weakness or breathing difficulties, the FDA cautioned. Daxxify study participants showed none of those symptoms. Revance had initially hoped for approval of its product in November 2020, but plans were postponed because of pandemic travel restrictions, thereported. An inspection finally conducted in June 2021 found problems with the quality control process and the company’s working cell bank, which contain the drug’s active ingredient. Those concerns were resolved, the
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves New Botox RivalThe U.S. Food and Drug Administration approved a new antiwrinkle treatment that could be the most formidable challenger to date to market leader Botox
Read more »
FDA Approves Botox Challenger Daxxify for Frown LinesDaxibotulinumtoxinA-lanm is the first and only peptide-formulated neuromodulator to reduce frown lines, with results lasting longer than conventional neuromodulators, according to the manufacturer.
Read more »
In reversal, FDA panel votes to recommend experimental ALS drugIn an unusual move, the FDA advisory panel convened for the second time in less than a year to review Amylyx's drug for amyotrophic lateral sclerosis.
Read more »
FDA panel backs much-debated ALS drug in rare, 2nd reviewWASHINGTON (AP) — A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group earlier this year.
Read more »